Company* Product Description Indication Action/Date Acambis plc (UK; ACAMF) ACAM2000 Smallpox vaccine; a clonal isolate of Dryvax that is manufactured using cell-culture technology Smallpox An FDA advisory committee voted 11-0 that ACAM2000 is safe and effective for use in high-risk situations (5/17) Biogen Idec Inc. (BIIB) and Elan Corp. plc (Ireland; NYSE:ELN) Tysabri (FDA-approved) Natalizumab Crohn's disease A joint FDA advisory panel gave a positive recommendation for approval (8/1
State of the Industry Report | Sunday, October 18, 2009
Company* (Symbol) Product Description Indication Action/Date Abbott Laboratories (NYSE:ABT) Humira (FDA-approved) Adalimumab; fully human antibody designed to block TNF-alpha Juvenile rheumatoic arthritis; juvenile idiopathic arthritis Submitted an sBLA with the FDA and a Type II Variation to the EMEA seeking approval to market Humira for juvenile RA in the U.S. and for juvenile idiopathic arthritis in the European Union (5/7) Adolor Corp. (ADLR) Entereg A peripherally acting muopioid
State of the Industry Report | Sunday, October 18, 2009
Total: $6,230.1M Company Location Date Amt. (M) Details JANUARY 4-Antibody AG Basel, Switzerland 1/16/07 CHF17 (US$13.6) 4-Antibody raised CHF17M in its Series A round led by Advent Venture Partners; other investors were Biomedinvest AG, Grazia Equity GmbH, Life Sciences Partners and Mulligan Biocapital AG, as well as several private investors Althea Technologies Inc. San Diego 1/9/07 $23 Investing in the Series C financing investment were funds managed by Telegraph Hill Partners
State of the Industry Report | Sunday, August 23, 2009
Company* (Symbol) Product Description Indication Action/Date Adolor Corp. (ADLR) Entereg A peripherally acting muopioid receptor antagonist; alvimopan Postoperative ileus FDA accepted the complete response to an approvable letter (8/28) Amylin Pharmaceuticals Inc. (AMLN) Symlin (FDA-approved) Pramlintide acetate Type II diabetes FDA issued a non-approvable letter for Symlin use with basal insulin in patients who have not achieved desired glucose control (10/1) Avanir Pharmaceuticals
State of the Industry Report | Friday, August 7, 2009
Company* (Symbol) Product Description Indication Action/Date Abbott Laboratories (NYSE:ABT) Humira (FDA-approved) Adalimumab; fully human antibody designed to block TNF-alpha Moderately to severely active Crohn's disease FDA approved Humira as a treatment for reducing the signs and symptoms, and inducing and maintaining clinical remission in adults who have had an inadequate response to conventional therapy (2/27) Abraxis BioScience Inc. (ABBI) Oxytocin A new dose injection To initiate or
State of the Industry Report | Friday, August 7, 2009
Biotech Co.* (Country; Symbol) Agbiotech Partner (Country Symbol) Type/Product Area Terms/Details (Date) Accera Inc.* Nestle Purina PetCare Global Resources Inc. Nestle Purina got rights to develop Accera's AC-1203 for treating aging conditions in dogs and other companion animals The agent will be developed for canine cognitive dysfunction and other conditions; Accera gets an up-front payment, and is eligible to receive milestone payments (1/8) Aureus Pharma* (France) Bayer CropScience
State of the Industry Report | Monday, July 20, 2009
I. MODIFIED AGREEMENTS Company* (Country; Symbol) Company* (Country; Symbol) Change from original agreement Terms/Details (Date) FIRST QUARTER ActiveSight* Lexicon Genetics Inc. (LEXG) ActiveSight will provide crystallography services for multiple Lexicon targets The expanded deal is the third between the companies; terms were not disclosed (1/5) Argenta Discovery Ltd.* (UK) Genentech Inc. (NYSE:DNA) Expanded drug discovery agreement to add a second two-year discovery project The
State of the Industry Report | Monday, July 20, 2009
U.S. Public Follow-on Stock Offerings Company Offering Month Offering Price 2007 Close % Change Acadia Pharmaceuticals Inc. April $15.50 $11.07 -29% Acorda Therapeutics Inc. June $18.50 $21.96 +19% Advanced Magnetics Inc. May $65.14 $60.13 -8% Alexza Pharmaceuticals Inc. April $10.25 $8.09 -21% Allos Therapeutics Inc. January $6 $6.29 +5% Altus Pharmaceuticals Inc. April $14.75 $5.18 -65% Anesiva Inc. December $4.05 $5 +23% A.P. Pharma Inc. June $1.65 $1.58 -4% Aradigm Corp
State of the Industry Report | Monday, July 20, 2009
Initial Public Offerings on U.S. Markets Company Offering Month Offering Price 2007 Close* % Change 3SBIO Inc. February $16 $14.88 -7% Amicus Therapeutics Inc. May $15 $10.75 -28% ARYx Therapeutics Inc. November $10 $7.75 -23% Biodel Inc. May $15 $23.23 +55% Eurand International SpA May $16 $15.80 -1% Genoptix Inc. October $17 $30.70 +81% Helicos BioSciences Corp. May $9 $10.44 +16% ImaRx Therapeutics Inc. July $5 $1.93 -61% Jazz Pharmaceuticals Inc. June $18 $14.70 -18% MAP
State of the Industry Report | Monday, July 20, 2009
January December 2007 Follow-on Offerings Number of follow-on offerings in 2007: 51 Total raised in follow-ons in 2007: $3,038.16M Average value of follow-ons in 2007: $59.57M Company (Symbol) Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Lead, Other Underwriters Gross (M) Post-Offering Market Cap (M)@ JANUARY Allos Therapeutics Inc. (ALTH) 1/30 1/30 9S $6 65.7 Merrill Lynch & Co. Banc of America (Co-lead) JMP Securities LLC $54 $394.2 Aradigm Corp. (ARDM) 10/24/06 1
State of the Industry Report | Monday, July 20, 2009
Number of IPOs in 2007: 41 Total raised in IPOs in 2007: $2,086.81M Average value of IPOs in 2007: $50.9M Company (Symbol) Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Lead, Other Underwriters Gross (M) Post-Offering Market Cap (M)@ JANUARY There were no initial public offerings that commenced in January. FEBRUARY 3SBIO Inc. (China; SSRX) 1/22/07 2/7/07 7.2S $16 150.3 UBS Investment Bank CIBC World Markets Pacific Growth Equities $115.2 $344.2 BioLineRx Ltd
State of the Industry Report | Monday, July 20, 2009
(in Millions of Dollars) Public Offerings January 573.5 February 655.4 March 174.1 April 559.1 May 1,257.5 June 568.7 July 213.5 August 42.2 September 225.0 October 484.5 November 293.0 December 78.6 Total 5,125.0 Public/Other January 230.1 February 1,334.3 March 865.1 April 901.3 May 4,684.0 June 1,956.8 July 370.6 August 530.0 September 207.9 October 709.2 November 880.3 December 749.1 Total 13,418.7 Private Biotechs January 518.7
State of the Industry Report | Monday, July 20, 2009
U.S. Public Follow-on Stock Offerings Company Offering Month Offering Price 2007 Close % Change Acadia Pharmaceuticals Inc. April $15.50 $11.07 -29% Acorda Therapeutics Inc. June $18.50 $21.96 +19% Advanced Magnetics Inc. May $65.14 $60.13 -8% Alexza Pharmaceuticals Inc. April $10.25 $8.09 -21% Allos Therapeutics Inc. January $6 $6.29 +5% Altus Pharmaceuticals Inc. April $14.75 $5.18 -65% Anesiva Inc. December $4.05 $5 +23% A.P. Pharma Inc. June $1.65 $1.58 -4% Aradigm Corp
State of the Industry Report | Saturday, October 11, 2008
Initial Public Offerings on U.S. Markets Company Offering Month Offering Price 2007 Close* % Change 3SBIO Inc. February $16 $14.88 -7% Amicus Therapeutics Inc. May $15 $10.75 -28% ARYx Therapeutics Inc. November $10 $7.75 -23% Biodel Inc. May $15 $23.23 +55% Eurand International SpA May $16 $15.80 -1% Genoptix Inc. October $17 $30.70 +81% Helicos BioSciences Corp. May $9 $10.44 +16% ImaRx Therapeutics Inc. July $5 $1.93 -61% Jazz Pharmaceuticals Inc. June $18 $14.70 -18% MAP
State of the Industry Report | Saturday, October 11, 2008
Company* Product Description Indication Action/Date Acambis plc (UK; ACAMF) ACAM2000 Smallpox vaccine; a clonal isolate of Dryvax that is manufactured using cell-culture technology Smallpox An FDA advisory committee voted 11-0 that ACAM2000 is safe and effective for use in high-risk situations (5/17) Biogen Idec Inc. (BIIB) and Elan Corp. plc (Ireland; NYSE:ELN) Tysabri (FDA-approved) Natalizumab Crohn's disease A joint FDA advisory panel gave a positive recommendation for approval (8/1